H.R.1734 — TRANQ Research Act of 2023
House Roll Call
H.R.1734
| Bill | H.R.1734 — TRANQ Research Act of 2023 |
|---|---|
| Vote question | On Motion to Suspend the Rules and Pass, as Amended |
| Vote type | 2/3 Yea-And-Nay |
| Result | Passed |
| Totals | Yea 425 / Nay 0 / Present 0 / Not Voting 10 |
| Party | Yea | Nay | Present | Not Voting |
|---|---|---|---|---|
| R | 219 | 0 | 0 | 3 |
| D | 206 | 0 | 0 | 7 |
| I | 0 | 0 | 0 | 0 |
Research Brief
On Motion to Suspend the Rules and Pass, as Amended
Bill Analysis
The TRANQ Research Act of 2023 (HR 1734) aims to address the growing public health crisis associated with the emergence and proliferation of synthetic opioids, particularly xylazine, commonly known as “tranq.” This legislation establishes a comprehensive framework for research and data collection on the effects and prevalence of tranq and similar substances.
Key Provisions: The Act mandates the National Institute on Drug Abuse (NIDA) to conduct and support research on the health impacts, patterns of use, and potential treatment options related to tranq. It also requires the Centers for Disease Control and Prevention (CDC) to enhance surveillance efforts to monitor the prevalence of tranq in drug overdoses and to analyze its interaction with other substances, particularly opioids.
Funding and Authorities: The legislation authorizes appropriations to support these research initiatives, although specific funding amounts are not detailed in the bill. The Act emphasizes collaboration between federal agencies, including the Substance Abuse and Mental Health Services Administration (SAMHSA) and the Food and Drug Administration (FDA), to facilitate a coordinated response to the challenges posed by tranq.
Programs and Agencies Affected: The primary agencies involved are NIDA, CDC, SAMHSA, and FDA. The Act encourages the development of educational programs aimed at healthcare providers and the public to raise awareness about the dangers of tranq.
Beneficiaries and Regulation: The Act benefits a broad range of stakeholders, including healthcare providers, researchers, and communities affected by substance use disorders. It aims to improve treatment options and public health responses, ultimately assisting individuals struggling with addiction and reducing overdose fatalities.
Key Timelines: The bill was introduced in the House and underwent a series of approvals before becoming Public Law No: 118-23. Implementation timelines for specific research initiatives and funding allocations will be determined by the respective agencies following the bill’s enactment.
Yea (425)
C
Colin Allred
K
Kelly Armstrong
D
Dan Bishop
E
Earl Blumenauer
J
Jamaal Bowman
K
Ken Buck
L
Larry Bucshon
M
Michael Burgess
C
Cori Bush
K
Ken Calvert
Y
Yadira Caraveo
T
Tony Cárdenas
J
Jerry Carl
M
Matt Cartwright
L
Lori Chavez-DeRemer
D
David Cicilline
G
Gerald Connolly
J
Jason Crow
A
Anthony D'Esposito
L
Lloyd Doggett
J
John Duarte
J
Jeff Duncan
A
Anna Eshoo
A
A. Ferguson
S
Scott Franklin
M
Matt Gaetz
M
Mike Gallagher
R
Ruben Gallego
J
John Garamendi
M
Mike Garcia
B
Bob Good
K
Kay Granger
G
Garret Graves
M
Mark Green
R
Raúl Grijalva
B
Brian Higgins
J
Jeff Jackson
S
Sheila Jackson Lee
B
Bill Johnson
D
Daniel Kildee
D
Derek Kilmer
A
Ann Kuster
D
Doug Lamborn
J
Jake LaTurner
B
Barbara Lee
D
Debbie Lesko
B
Blaine Luetkemeyer
K
Kathy Manning
L
Lucy McBath
K
Kevin McCarthy
L
Lisa McClain
P
Patrick McHenry
M
Marcus Molinaro
A
Alexander Mooney
G
Grace Napolitano
W
Wiley Nickel
B
Bill Pascrell
D
Donald Payne
M
Mary Peltola
D
Dean Phillips
K
Katie Porter
B
Bill Posey
C
Cathy Rodgers
M
Matthew Rosendale
J
John Rutherford
G
George Santos
J
John Sarbanes
D
David Schweikert
P
Pete Sessions
A
Abigail Spanberger
M
Michelle Steel
C
Chris Stewart
E
Eric Swalwell
R
Rashida Tlaib
N
Nydia Velázquez
M
Michael Waltz
D
Debbie Wasserman Schultz
B
Brad Wenstrup
J
Jennifer Wexton
S
Susan Wild
B
Brandon Williams
Not Voting (10)
G
Greg Pence
C
C. Ruppersberger
D
David Trone